Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 3/2020

01-09-2020 | Computed Tomography | Pulmonary Radiology (M Stephens and S Kapur, Section Editors)

Current Applications for Nuclear Medicine Imaging in Pulmonary Disease

Authors: Joanna E. Kusmirek, Josiah D. Magnusson, Scott B. Perlman

Published in: Current Pulmonology Reports | Issue 3/2020

Login to get access

Abstract

Purpose of Review

The main goal of the article is to familiarize the reader with commonly and uncommonly used nuclear medicine procedures that can significantly contribute to improved patient care. The article presents examples of specific modality utilization in the chest including assessment of lung ventilation and perfusion, imaging options for broad range of infectious and inflammatory processes, and selected aspects of oncologic imaging. In addition, rapidly developing new techniques utilizing molecular imaging are discussed.

Recent Findings

The article describes nuclear medicine imaging modalities including gamma camera, SPECT, PET, and hybrid imaging (SPECT/CT, PET/CT, and PET/MR) in the context of established and emerging clinical applications. Areas of potential future development in nuclear medicine are discussed with emphasis on molecular imaging and implementation of new targeted tracers used in diagnostics and therapeutics (theranostics).

Summary

Nuclear medicine and molecular imaging provide many unique and novel options for the diagnosis and treatment of pulmonary diseases. This article reviews current applications for nuclear medicine and molecular imaging and selected future applications for radiopharmaceuticals and targeted molecular imaging techniques.
Literature
1.
Eberl S, Chan HK, Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J Aerosol Med. 2006;19(1):8–20.PubMedCrossRef
2.
Hutton BF. The origins of SPECT and SPECT/CT. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S3–16.PubMedCrossRef
3.
Jacene H, Goetze S, Patel H, Wahl R, Ziessman H. Advantages of hybrid SPECT/CT vs SPECT alone. The Open Medical Imaging Journal. 2008;2:67–79.CrossRef
4.
Djekidel M, Brown RK, Piert M. Benefits of hybrid SPECT/CT for (111)In-oxine- and Tc-99m-hexamethylpropylene amine oxime-labeled leukocyte imaging. Clin Nucl Med. 2011;36(7):e50–6.PubMedCrossRef
5.
Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, et al. Two decades of SPECT/CT - the coming of age of a technology: an updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46(10):1990–2012.PubMedPubMedCentralCrossRef
6.
Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in oncology: current and emerging clinical applications. Clin Radiol. 2008;63(3):241–51.PubMedCrossRef
7.
Charest M, Asselin C. Effective dose in nuclear medicine studies and SPECT/CT: dosimetry survey across Quebec Province. Journal of nuclear medicine technology. 2018;46(2):107–13.PubMedCrossRef
8.
Rausch I, Fuchsel FG, Kuderer C, Hentschel M, Beyer T. Radiation exposure levels of routine SPECT/CT imaging protocols. Eur J Radiol. 2016;85(9):1627–36.PubMedCrossRef
9.
Montes C, Tamayo P, Hernandez J, Gomez-Caminero F, García S, Martín C, et al. Estimation of the total effective dose from low-dose CT scans and radiopharmaceutical administrations delivered to patients undergoing SPECT/CT explorations. Ann Nucl Med. 2013;27(7):610–7.PubMedCrossRef
10.
Schauer DA, Linton OW. NCRP report no. 160, ionizing radiation exposure of the population of the United States, medical exposure—are we doing less with more, and is there a role for health physicists? Health Phys. 2009;97(1):1–5.PubMedCrossRef
11.
12.
13.
Roach PJ, Schembri GP, Bailey DL. V/Q scanning using SPECT and SPECT/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54(9):1588–96.CrossRef
14.
Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). Jama. 1990;263(20):2753–9.CrossRef
15.
Gutte H, Mortensen J, Jensen CV, Johnbeck CB, von der Recke P, Petersen CL, et al. Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009;50(12):1987–92.CrossRef
16.
Jogi J, Ekberg M, Jonson B, Bozovic G, Bajc M. Ventilation/perfusion SPECT in chronic obstructive pulmonary disease: an evaluation by reference to symptoms, spirometric lung function and emphysema, as assessed with HRCT. Eur J Nucl Med Mol Imaging. 2011;38(7):1344–52.PubMedCrossRef
17.
18.
Giraudo C, Evangelista L, Fraia AS, Lupi A, Quaia E, Cecchin D, et al. Molecular imaging of pulmonary inflammation and infection. Int J Mol Sci. 2020;21(3):894.PubMedCentralCrossRef
19.
Dolovich M, Labiris R. Imaging drug delivery and drug responses in the lung. Proc Am Thorac Soc. 2004;1(4):329–37.PubMedCrossRef
20.
Robinson DS, Cunningham DA, Dave S, Fleming J, Mitchell DM. Diagnostic value of lung clearance of 99mTc DTPA compared with other non-invasive investigations in Pneumocystis carinii pneumonia in AIDS. Thorax. 1991;46(10):722–6.PubMedPubMedCentralCrossRef
21.
Deep A, Bhure SU, Bhure UN, Joshi SM, Bhatt BM, Desai SA, et al. Efficacy of 99mTc-DTPA lung clearance test in the diagnosis of PCP in HIV-positive patients. J Trop Pediatr. 2009;55(2):97–102.PubMedCrossRef
22.
Palestro CJ, Torres MA. Radionuclide imaging of nonosseous infection. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 1999;43(1):46–60.
23.
Goldfarb CR, Colp C, Ongseng F, Finestone H, Havas J. Gallium scanning in the ‘new’ tuberculosis. Clin Nucl Med. 1997;22(7):470–4.PubMedCrossRef
24.
Sathekge M, Maes A, D’Asseler Y, Vorster M, Van de Wiele C. Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals. Nucl Med Commun. 2012;33(6):581–90.PubMedCrossRef
25.
Schuster DM, Alazraki N. Gallium and other agents in diseases of the lung. Semin Nucl Med. 2002;32(3):193–211.PubMedCrossRef
26.
27.
28.
de Vries EF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37(4):842–8.PubMedPubMedCentralCrossRef
29.
Palestro CJ, Love C, Miller TT. Diagnostic imaging tests and microbial infections. Cell Microbiol. 2007;9(10):2323–33.PubMedCrossRef
30.
Love C, Opoku-Agyemang P, Tomas MB, Pugliese PV, Bhargava KK, Palestro CJ. Pulmonary activity on labeled leukocyte images: physiologic, pathologic, and imaging correlation. RadioGraphics. 2002;22(6):1385–93.PubMedCrossRef
31.
Koranda P, Drymlová J, Malý T, Kantor L, Ptácek J, Myslivecek M. Tc-99m exametazime (HMPAO)-labeled leukocyte scintigraphy in premature infants: detection and localization of necrotic enterocolitis and osteomyelitis. Clin Nucl Med. 2011;36(6):e35–e6.PubMedCrossRef
32.
Tregay N, Begg M, Cahn A, Farahi N, Povey K, Madhavan S, et al. Use of autologous <sup>99m</sup>technetium-labelled neutrophils to quantify lung neutrophil clearance in COPD. Thorax. 2019;74(7):659–66.PubMedCrossRef
33.
Gaeta GB, Fusco FM, Nardiello S. Fever of unknown origin: a systematic review of the literature for 1995-2004. Nucl Med Commun. 2006;27(3):205–11.PubMedCrossRef
34.
Mulders-Manders C, Simon A, Bleeker-Rovers C. Fever of unknown origin. Clin Med (Lond). 2015;15(3):280–4.CrossRef
35.
Signore A, Jamar F, Israel O, Buscombe J, Martin-Comin J, Lazzeri E. Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline. Eur J Nucl Med Mol Imaging. 2018;45(10):1816–31.PubMedPubMedCentralCrossRef
36.
Królicki L. “To be or not to be” for PET in rheumatology. A marriage of love or of convenience? Reumatologia. 2017;55(1):1–3.PubMedPubMedCentral
37.
Ergul N, Cermik TF. FDG-PET or PET/CT in fever of unknown origin: the diagnostic role of underlying primary disease. Int J Mol Imaging. 2011;2011:318051.PubMedPubMedCentralCrossRef
38.
Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest. 2007;132(6):1949–53.PubMedCrossRef
39.
40.
Kashefi A, Kuo J, Shelton DK. Molecular imaging in pulmonary diseases. AJR Am J Roentgenol. 2011;197(2):295–307.PubMedCrossRef
41.
Franzius C, Biermann M, Hülskamp G, Frosch M, Roth J, Sciuk J, et al. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin Nucl Med. 2001;26(3):232–3.PubMedCrossRef
42.
Reuter S, Schirrmeister H, Kratzer W, Dreweck C, Reske SN, Kern P. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis. 1999;29(5):1157–63.PubMedCrossRef
43.
Yibulayin A, Li XH, Qin YD, Jia XY, Zhang QZ, Li YB. Biological characteristics of 18F-FDG PET/CT imaging of cerebral alveolar echinococcosis. Medicine. 2018;97(39):e11801.PubMedPubMedCentralCrossRef
44.
Becker W, Meller J. The role of nuclear medicine in infection and inflammation. Lancet Infect Dis. 2001;1(5):326–33.PubMedCrossRef
45.
Hess S, Alavi A, Basu S. PET-based personalized management of infectious and inflammatory disorders. PET clinics. 2016;11(3):351–61.PubMedCrossRef
46.
Treglia G. Diagnostic performance of (18)F-FDG PET/CT in infectious and inflammatory diseases according to published meta-analyses. Contrast Media Mol Imaging. 2019;2019:3018349.PubMedPubMedCentralCrossRef
47.
Kumar NS, Shejul Y, Asopa R, Basu S. Quantitative metabolic volumetric product on (18)fluorine-2fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in assessing treatment response to disease-modifying antirheumatic drugs in rheumatoid arthritis: multiparametric analysis integrating American College of Rheumatology/European League against rheumatism criteria. World J Nucl Med. 2017;16(4):293–302.PubMedPubMedCentralCrossRef
48.
Rehak Z, Sprlakova-Pukova A, Kazda T, Fojtik Z, Vargova L, Nemec P. (18)F-FDG PET/CT in polymyalgia rheumatica-a pictorial review. Br J Radiol. 2017;90(1076):20170198.PubMedPubMedCentralCrossRef
49.
Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. (18) F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439–49.PubMedPubMedCentralCrossRef
50.
Yamashita H, Kubota K, Takahashi Y, Minamimoto R, Morooka M, Kaneko H, et al. Clinical value of (1)(8)F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still’s disease: a seven-case series and review of the literature. Mod Rheumatol. 2014;24(4):645–50.PubMedCrossRef
51.
An YS, Suh CH, Jung JY, Cho H, Kim HA. The role of 18F-fluorodeoxyglucose positron emission tomography in the assessment of disease activity of adult-onset Still’s disease. Korean J Intern Med. 2017;32(6):1082–9.PubMedCrossRef
52.
Hotta M, Minamimoto R, Kaneko H, Yamashita H. Fluorodeoxyglucose PET/CT of arthritis in rheumatic diseases: a pictorial review. RadioGraphics. 2020;40(1):223–40.PubMedCrossRef
53.
Wang J, Li S, Zeng Y, Chen P, Zhang N, Zhong N. (1)(8)F-FDG PET/CT is a valuable tool for relapsing polychondritis diagnose and therapeutic response monitoring. Ann Nucl Med. 2014;28(3):276–84.PubMedCrossRef
54.
Yamashita H, Takahashi H, Kubota K, Ueda Y, Ozaki T, Yorifuji H, et al. Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: a case series and literature review. Rheumatology (Oxford, England). 2014;53(8):1482–90.CrossRef
55.
Kubota K, Yamashita H, Mimori A. Clinical value of FDG-PET/CT for the evaluation of rheumatic diseases: rheumatoid arthritis, polymyalgia Rheumatica, and relapsing polychondritis. Semin Nucl Med. 2017;47(4):408–24.PubMedCrossRef
56.
Notni J, Gassert FT, Steiger K, Sommer P, Weichert W, Rummeny EJ, et al. In vivo imaging of early stages of rheumatoid arthritis by alpha5beta1-integrin-targeted positron emission tomography. EJNMMI Res. 2019;9(1):87.PubMedPubMedCentralCrossRef
57.
Auletta S, Galli F, Lauri C, Martinelli D, Santino I, Signore A. Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review. Clin Transl Imaging. 2016;4:229–52.PubMedPubMedCentralCrossRef
58.
Welling MM, Hensbergen AW, Bunschoten A, Velders AH, Roestenberg M, van Leeuwen FWB. An update on radiotracer development for molecular imaging of bacterial infections. Clinical and Translational Imaging. 2019;7(2):105–24.CrossRef
59.
Lawal I, Zeevaart J, Ebenhan T, Ankrah A, Vorster M, Kruger HG, et al. Metabolic imaging of infection. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58(11):1727–32.CrossRef
60.
Kartamihardja AHS, Kurniawati Y, Gunawan R. Diagnostic value of (99m)Tc-ethambutol scintigraphy in tuberculosis: compared to microbiological and histopathological tests. Ann Nucl Med. 2018;32(1):60–8.PubMedCrossRef
61.
Signore A, Lauri C, Auletta S, Anzola K, Galli F, Casali M, et al. Immuno-imaging to predict treatment response in infection, inflammation and oncology. J Clin Med. 2019;8(5):681.PubMedCentralCrossRef
62.
Auletta S, Varani M, Horvat R, Galli F, Signore A, Hess S. PET radiopharmaceuticals for specific bacteria imaging: a systematic review. J Clin Med. 2019;8(2):197.PubMedCentralCrossRef
63.
Zheng L, Ding X, Liu K, Feng S, Tang B, Li Q, et al. Molecular imaging of fibrosis using a novel collagen-binding peptide labelled with (99m)Tc on SPECT/CT. Amino Acids. 2017;49(1):89–101.PubMedCrossRef
64.
65.
Désogère P, Montesi SB, Caravan P. Molecular probes for imaging fibrosis and fibrogenesis. Chem Eur J. 2019;25(5):1128–41.PubMedCrossRef
66.
Désogère P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, et al. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017;9(384):eaaf4696.
67.
Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJR. The role of new PET tracers for lung cancer. Lung cancer (Amsterdam, Netherlands). 2016;94:7–14.CrossRef
68.
Maffione AM, Grassetto G, Rampin L, Chondrogiannis S, Marzola MC, Ambrosini V, et al. Molecular imaging of pulmonary nodules. AJR Am J Roentgenol. 2014;202(3):W217–23.PubMedCrossRef
69.
Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012;53(3):443–50.CrossRef
70.
Memon AA, Weber B, Winterdahl M, Jakobsen S, Meldgaard P, Madsen HH, et al. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer. Br J Cancer. 2011;105(12):1850–5.PubMedPubMedCentralCrossRef
71.
van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, et al. Molecular imaging biomarkers for immune checkpoint inhibitor therapy. Theranostics. 2020;10(4):1708–18.PubMedPubMedCentralCrossRef
72.
Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9(1):4664.PubMedPubMedCentralCrossRef
73.
Greenspan BS. Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. Translational lung cancer research. 2017;6(6):617–20.PubMedPubMedCentralCrossRef
74.
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2003;97(4):934–59.CrossRef
75.
Baxi AJ, Chintapalli K, Katkar A, Restrepo CS, Betancourt SL, Sunnapwar A. Multimodality imaging findings in carcinoid tumors: a head-to-toe spectrum. RadioGraphics. 2017;37(2):516–36.PubMedCrossRef
76.
Lococo F, Stefani A, Treglia G. Is fludeoxyglucose-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG-PET/CT) really useless in staging pulmonary carcinoid tumors and in discriminating histological subtypes? Controversial points and future perspectives. Ann Thorac Med. 2015;10(3):217–8.PubMedPubMedCentralCrossRef
77.
Jiang Y, Hou G, Cheng W. The utility of 18F-FDG and 68Ga-DOTA-peptide PET/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis. Medicine. 2019;98(10):e14769-e.
78.
Deroose CM, Hindie E, Kebebew E, Goichot B, Pacak K, Taieb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016;57(12):1949–56.CrossRef
79.
Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS. Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. Radiographics. 2006;26(1):41–57.PubMedCrossRef
80.
Yankeelov TE, Peterson TE, Abramson RG, Izquierdo-Garcia D, Arlinghaus LR, Li X, et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? Magn Reson Imaging. 2012;30(9):1342–56.PubMedPubMedCentralCrossRef
81.
Chen DL, Kinahan PE. Multimodality molecular imaging of the lung. Journal of magnetic resonance imaging : JMRI. 2010;32(6):1409–20.PubMedCrossRef
82.
Raad RA, Friedman KP, Heacock L, Ponzo F, Melsaether A, Chandarana H. Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy. J Magn Reson Imaging. 2016;43(2):504–11.PubMedCrossRef
83.
Schwenzer NF, Seith F, Gatidis S, Brendle C, Schmidt H, Pfannenberg CA, et al. Diagnosing lung nodules on oncologic MR/PET imaging: comparison of fast T1-weighted sequences and influence of image acquisition in inspiration and expiration breath-hold. Korean J Radiol. 2016;17(5):684–94.PubMedPubMedCentralCrossRef
84.
Fernandez-Perez G, Sanchez-Escribano R, Garcia-Vicente AM, Luna-Alcala A, Ceballos-Viro J, Delgado-Bolton RC, et al. SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. Clin Transl Oncol. 2018;20(7):837–52.PubMedCrossRef
85.
Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, et al. Thoracic staging with (18)F-FDG PET/MR in non-small cell lung cancer-does it change therapeutic decisions in comparison to (18)F-FDG PET/CT? Eur Radiol. 2017;27(2):681–8.PubMedCrossRef
86.
Treglia G, Sadeghi R, Annunziata S, Lococo F, Cafarotti S, Bertagna F, et al. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. Acad Radiol. 2014;21(1):11–20.PubMedCrossRef
87.
Brun C, Gay P, Cottier M, Karpathiou G, Patoir A, Tiffet O, et al. Comparison of cytology, chest computed and positron emission tomography findings in malignant pleural effusion from lung cancer. Journal of thoracic disease. 2018;10(12):6903–11.PubMedPubMedCentralCrossRef
88.
Porcel JM, Hernandez P, Martinez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147(2):502–12.PubMedCrossRef
89.
Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol. 2009;4(12):1480–4.PubMedCrossRef
90.
Sun Y, Yu H, Ma J, Lu P. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8):e0161764.PubMedPubMedCentralCrossRef
91.
de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, et al. Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial). BMJ Open Respir Res. 2018;5(1):e000270.PubMedPubMedCentralCrossRef
92.
Holcman K, Szot W, Rubis P, Lesniak-Sobelga A, Hlawaty M, Wisniowska-Smialek S, et al. 99mTc-HMPAO-labeled leukocyte SPECT/CT and transthoracic echocardiography diagnostic value in infective endocarditis. The international journal of cardiovascular imaging. 2019;35(4):749–58.PubMedCrossRef
93.
Hyafil F, Rouzet F, Lepage L, Benali K, Raffoul R, Duval X, et al. Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(6):586–94.PubMedCrossRef
94.
Rouzet F, Chequer R, Benali K, Lepage L, Ghodbane W, Duval X, et al. Respective performance of 18F-FDG PET and radiolabeled leukocyte scintigraphy for the diagnosis of prosthetic valve endocarditis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014;55(12):1980–5.CrossRef
95.
Chen W, Dilsizian V. FDG PET/CT for the diagnosis and management of infective endocarditis: expert consensus vs evidence-based practice. J Nucl Cardiol. 2019;26(1):313–5.PubMedCrossRef
96.
Fiorani P, Speziale F, Rizzo L, De Santis F, Massimi GJ, Taurino M, et al. Detection of aortic graft infection with leukocytes labeled with technetium 99m-hexametazime. J Vasc Surg. 1993, 17(1):87–95 discussion −6.
97.
Erba PA, Leo G, Sollini M, Tascini C, Boni R, Berchiolli RN, et al. Radiolabelled leucocyte scintigraphy versus conventional radiological imaging for the management of late, low-grade vascular prosthesis infections. Eur J Nucl Med Mol Imaging. 2014;41(2):357–68.PubMedCrossRef
98.
Fujii T, Watanabe Y. Multidisciplinary treatment approach for prosthetic vascular graft infection in the thoracic aortic area. Ann Thorac Cardiovasc Surg. 2015;21(5):418–27.PubMedPubMedCentralCrossRef
99.
Palestro CJ, Love C, Tronco GG, Tomas MB. Role of radionuclide imaging in the diagnosis of postoperative infection. RadioGraphics. 2000;20(6):1649–60.PubMedCrossRef
100.
Erba PA, Sollini M, Conti U, Bandera F, Tascini C, De Tommasi SM, et al. Radiolabeled WBC scintigraphy in the diagnostic workup of patients with suspected device-related infections. JACC Cardiovasc Imaging. 2013;6(10):1075–86.PubMedCrossRef
101.
Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128.PubMedCrossRef
102.
Hitzel A, Manrique A, Etienne M, Chastan M, Salles A, Edet-Sanson A, et al. 99mTc leukocyte SPECT/CT for diagnosis of left ventricular assist device (LVAD) infection. Journal of Nuclear Medicine. 2009;50(supplement 2):1343.
103.
Litzler P-Y, Manrique A, Etienne M, Salles A, Edet-Sanson A, Vera P, et al. Leukocyte SPECT/CT for detecting infection of left-ventricular-assist devices: preliminary results. J Nucl Med. 2010;51(7):1044–8.PubMedCrossRef
104.
Kim GE, Sung IY, Ko EJ, Choi KH, Kim JS. Comparison of videofluoroscopic swallowing study and radionuclide salivagram for aspiration pneumonia in children with swallowing difficulty. Ann Rehabil Med. 2018;42(1):52–8.PubMedPubMedCentralCrossRef
105.
Jang DH, Choi KH, Kim DH, Lim CM, Kim JS. Comparison between the radionuclide salivagram and videofluoroscopic swallowing study methods for evaluating patients with aspiration pneumonia. Ann Nucl Med. 2013;27(3):247–52.PubMedCrossRef
106.
Park D, Woo SB, Lee DH, Yu KJ, Cho JY, Kim JM, et al. The correlation between clinical characteristics and radionuclide salivagram findings in patients with brain lesions: a preliminary study. Ann Rehabil Med. 2017;41(6):915–23.PubMedPubMedCentralCrossRef
107.
Yang M, Covington MF, Nguyen BD, Johnson GB, Mesa RA, Roarke MC. (99m)Tc-sulfur colloid bone marrow Scintigraphy in diagnosis of diffuse pulmonary extramedullary hematopoiesis secondary to myelofibrosis. Journal of nuclear medicine technology. 2018;46(4):368–72.PubMedPubMedCentralCrossRef
108.
Yammine JN, Yatim A, Barbari A. Radionuclide imaging in thoracic splenosis and a review of the literature. Clin Nucl Med. 2003;28(2):121–3.PubMed
109.
Houshmand S, Salavati A, Hess S, Ravina M, Alavi A. The role of molecular imaging in diagnosis of deep vein thrombosis. American journal of nuclear medicine and molecular imaging. 2014;4(5):406–25.PubMedPubMedCentral
110.
Morris TA. SPECT imaging of pulmonary emboli with radiolabeled thrombus-specific imaging agents. Semin Nucl Med. 2010;40(6):474–9.PubMedCrossRef
111.
Dunzinger A, Hafner F, Schaffler G, Piswanger-Soelkner J-C, Brodmann M, Lipp RW. 99mTc-apcitide scintigraphy in patients with clinically suspected deep venous thrombosis and pulmonary embolism. Eur J Nucl Med Mol Imaging. 2008;35(11):2082–7.PubMedCrossRef
112.
Macfarlane D, Socrates A, Eisenberg P, Larcos G, Roach P, Gerometta M, et al. Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial. Eur J Nucl Med Mol Imaging. 2009;36(2):250–9.PubMedCrossRef
113.
Douketis JD, Ginsberg JS, Haley S, Julian J, Dwyer M, Levine M, et al. Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study. Thromb Res. 2012;130(3):381–9.PubMedCrossRef
114.
Ciesienski KL, Yang Y, Ay I, Chonde DB, Loving GS, Rietz TA, et al. Fibrin-targeted PET probes for the detection of thrombi. Mol Pharm. 2013;10(3):1100–10.PubMedPubMedCentralCrossRef
115.
Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019;60(Suppl 2):13s–19s.
116.
Bonniaud P, Burgy O, Garrido C. Heat shock protein-90 toward theranostics: a breath of fresh air in idiopathic pulmonary fibrosis. Eur Respir J. 2018;51(2):1702612.PubMedCrossRef
117.
Bellaye P-S, Shimbori C, Yanagihara T, Carlson DA, Hughes P, Upagupta C, et al. Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. Eur Respir J. 2018;51(2):1700386.PubMedCrossRef
Metadata
Title
Current Applications for Nuclear Medicine Imaging in Pulmonary Disease
Authors
Joanna E. Kusmirek
Josiah D. Magnusson
Scott B. Perlman
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 3/2020
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-020-00251-1

Other articles of this Issue 3/2020

Current Pulmonology Reports 3/2020 Go to the issue

Environmental and Occupational Health (S Cherian, Section Editor)

Imaging in Occupational and Environmental Lung Disease

Pulmonary Radiology (M Stephens and S Kapur, Section Editors)

Intrathoracic Manifestations of Sarcoidosis: an Imaging Review Highlighting Atypical Features

Sleeping and Breathing (A Abreu, Section Editor)

Management of Insomnia in Chronic Lung Diseases

Sleeping and Breathing (A Abreu, Section Editor)

Cannabinoids and Sleep: Helpful or Harmful?

Sleeping and Breathing (A Abreu, Section Editor)

Sleep, Obstructive Sleep Apnea, and Chronic Alveolar Hypoventilation in Cystic Fibrosis: Role of Noninvasive Ventilation During Sleep
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits